Drugs facing NCE-1 in 2030
Drugs becoming eligible for first Paragraph IV ANDA filing in 2030
1. Adquey patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46792 | ACROTECH | NA |
Mar, 2028
(1 year, 9 months from now) | |
| US10588893 | ACROTECH | Ointment Containing An Oxazole Compound |
Dec, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2031 |
Drugs and Companies using DIFAMILAST ingredient
NCE-1 date: 12 February, 2030
Market Authorisation Date: 12 February, 2026
Treatment: Method of treating atopic dermatitis
Dosage: OINTMENT
More Information on Dosage
ADQUEY family patents
2. Bysanti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10570453 | VANDA | Method Of Predicting A Predisposition To Qt Prolongation |
Mar, 2028
(1 year, 10 months from now) | |
| US9157121 | VANDA | Method of treatment based on polymorphisms of the KCNQ1 gene |
Apr, 2030
(3 years from now) | |
| US10563259 | VANDA | Method Of Treatment Based On Polymorphisms Of The Kcnq1 Gene |
Jul, 2030
(4 years from now) | |
| US8999638 | VANDA | Method of treatment based on polymorphisms of the KCNQ1 gene |
Oct, 2030
(4 years from now) | |
| US9074255 | VANDA | Method of predicting a predisposition to QT prolongation |
Dec, 2030
(4 years from now) | |
| US9072742 | VANDA | Method of predicting a predisposition to QT prolongation |
Jan, 2031
(4 years from now) | |
| US9074256 | VANDA | Method of predicting a predisposition to QT prolongation |
Feb, 2031
(4 years from now) | |
| US9074254 | VANDA | Method of predicting a predisposition to QT prolongation |
Dec, 2031
(5 years from now) | |
| US12478619 | VANDA | Method Of Treatment With Milsaperidone |
May, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 20, 2031 |
Drugs and Companies using MILSAPERIDONE ingredient
NCE-1 date: 20 February, 2030
Market Authorisation Date: 20 February, 2026
Treatment: Method for acute treatment of manic or mixed episodes associated with bipolar i disorder in adults by administering milsaperidone to a patient by lowering the dose after determining that the patient h...
Dosage: TABLET
More Information on Dosage
BYSANTI family patents
3. Foundayo patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE50455 | ELI LILLY | NA |
Sep, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 01, 2031 |
Drugs and Companies using ORFORGLIPRON CALCIUM ingredient
NCE-1 date: 01 April, 2030
Market Authorisation Date: 01 April, 2026
Treatment: Treatment to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition by administering an effective am...
Dosage: TABLET
More Information on Dosage
FOUNDAYO family patents
4. Icotyde patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12552836 | JANSSEN | NA |
Jul, 2039
(13 years from now) | |
| US11845808 | JANSSEN | Peptide Inhibitors Of Interleukin-23 Receptor And Their Use To Treat Inflammatory Diseases |
Jan, 2041
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11939361 | JANSSEN | Compositions Of Peptide Inhibitors Of Interleukin-23 Receptor |
Nov, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 17, 2031 |
Drugs and Companies using ICOTROKINRA HYDROCHLORIDE ingredient
NCE-1 date: 17 March, 2030
Market Authorisation Date: 17 March, 2026
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy
Dosage: TABLET
More Information on Dosage
ICOTYDE family patents
5. Lifyorli (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11576907 | CORCEPT | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
May, 2033
(7 years from now) | |
| US8859774 | CORCEPT | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
May, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9273047 | CORCEPT | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
May, 2033
(7 years from now) | |
| US10456392 | CORCEPT | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
May, 2033
(7 years from now) | |
| US12514849 | CORCEPT | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound |
Dec, 2039
(13 years from now) | |
| US11925626 | CORCEPT | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound |
Dec, 2039
(13 years from now) | |
| US11464764 | CORCEPT | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound |
Apr, 2040
(13 years from now) | |
| US12589094 | CORCEPT | NA |
May, 2041
(15 years from now) | |
| US11285145 | CORCEPT | Concomitant Administration Of Glucocorticoid Receptor Modulator Relacorilant And Paclitaxel, A Dual Substrate Of Cyp2C8 And Cyp3A4 |
May, 2041
(15 years from now) | |
| US12152028 | CORCEPT | Methods Of Preparing Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
Dec, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2031 |
Drugs and Companies using RELACORILANT ingredient
NCE-1 date: 25 March, 2030
Market Authorisation Date: 25 March, 2026
Treatment: Treatment of platinum-resistant primary peritoneal cancer with lifyorli in combination with nab-paclitaxel, in adults who have received one to three prior systemic treatment regimens, at least one of ...
Dosage: CAPSULE
More Information on Dosage
LIFYORLI (COPACKAGED) family patents
6. Lynavoy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9040518 | GLAXOSMITHKLINE | Chemical Compounds |
Sep, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 17, 2031 |
| Orphan Drug Exclusivity(ODE-517) | Mar 17, 2033 |
Drugs and Companies using LINERIXIBAT ingredient
NCE-1 date: 17 March, 2030
Market Authorisation Date: 17 March, 2026
Treatment: NA
Dosage: TABLET
More Information on Dosage
LYNAVOY family patents
7. Yuviwel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8906847 | ASCENDIS | Prodrug comprising a drug linker conjugate |
Apr, 2031
(4 years from now) | |
| US10835578 | ASCENDIS | Cnp Prodrugs With Large Carrier Moieties |
Jan, 2037
(10 years from now) | |
| US11389510 | ASCENDIS | Controlled-Release Cnp Agonists With Low Initial Npr-B Activity |
Jan, 2037
(10 years from now) | |
| US11413351 | ASCENDIS | Cnp Prodrugs With Carrier Attachment At The Ring Moiety |
Jan, 2037
(10 years from now) | |
| US11154593 | ASCENDIS | Cnp Prodrugs With Large Carrier Moieties |
Jan, 2037
(10 years from now) | |
| US11224661 | ASCENDIS | Controlled-Release Cnp Agonists With Increased Nep Stability |
Jan, 2037
(10 years from now) | |
| US11311604 | ASCENDIS | Controlled-Release Cnp Agonists With Low Npr-C Binding |
Jan, 2037
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12083182 | ASCENDIS | Controlled-Release Cnp Agonists With Increased Nep Stability |
Jan, 2037
(10 years from now) | |
| US11389511 | ASCENDIS | Controlled-Release Cnp Agonists With Reduced Side-Effects |
Jan, 2037
(10 years from now) | |
| US12239689 | ASCENDIS | Controlled-Release Cnp Agonists With Low Initial Npr-B Activity |
Jan, 2037
(10 years from now) | |
| US12156917 | ASCENDIS | Cnp Prodrugs With Carrier Attachment At The Ring Moiety |
Jan, 2037
(10 years from now) | |
| US12377133 | ASCENDIS | Dry Pharmaceutical Formulations Of Cnp Conjugates |
Nov, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 27, 2031 |
| Orphan Drug Exclusivity(ODE-516) | Feb 27, 2033 |
Drugs and Companies using NAVEPEGRITIDE ingredient
NCE-1 date: 27 February, 2030
Market Authorisation Date: 27 February, 2026
Treatment: Increase of linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses
Dosage: POWDER
More Information on Dosage
YUVIWEL family patents